Response rates vs cytogenetic risk categories for the efficacy analysis set. (A-B) Heat map showing IPSS-R, IPSS-M, and IPSS-R cytogenetic risk categories, best overall response, baseline comutations, baseline VAF, and OS in the efficacy analysis set (A; N = 18) and distribution of number of comutated genes with best overall response (B; N = 18). Please note that the numbers within the boxes correspond to the VAF of the alteration. ^aIf a patient had multiple alterations in a gene, the largest VAF was shown. ^bThis patient did not have any of the comutations evaluated in the panel but did have a poor-risk karyotype, including monosomy 7. PDis, progressive disease; RTK, receptor tyrosine kinase; SD, stable disease.